Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL4557546 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL2391146 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL2456472 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL6704394 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL861591 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL4304807 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL7695098 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL5133360 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL1395290 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL5091282 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| EP-1713475-B1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-07-30 | — | — | EP | disclosed |
| EP-1798231-A2 | Intermediate products for the preparation of antibacterial compounds | NOVEXEL (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1399444-B1 | NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS | NOVEXEL (FR) | 2007-04-11 | — | — | EP | disclosed |
| EP-1713475-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074920-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-18 | — | — | WO | disclosed |
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-08-04 | — | — | US | disclosed |
| EP-1130017-B1 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-0934937-B1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMA CO LTD (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1130017-A2 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | ALDH1A1 100/4885TDP1 661/4885TRPA1 4885/4885 |
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR2, CNR1, TBXA2R | ALDH1A1 1262/4885TDP1 4401/4885TRPA1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.